JP2017536352A - コパンリシブおよびそれの2塩酸塩の合成 - Google Patents
コパンリシブおよびそれの2塩酸塩の合成 Download PDFInfo
- Publication number
- JP2017536352A JP2017536352A JP2017523873A JP2017523873A JP2017536352A JP 2017536352 A JP2017536352 A JP 2017536352A JP 2017523873 A JP2017523873 A JP 2017523873A JP 2017523873 A JP2017523873 A JP 2017523873A JP 2017536352 A JP2017536352 A JP 2017536352A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- optionally
- solvent
- copan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003786 synthesis reaction Methods 0.000 title description 12
- 230000015572 biosynthetic process Effects 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 13
- 229910052742 iron Inorganic materials 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 11
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 10
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 10
- 229910052763 palladium Inorganic materials 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- -1 dicyclohexylamine Chemical class 0.000 claims description 7
- 229910017604 nitric acid Inorganic materials 0.000 claims description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000007822 coupling agent Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- PZSJOBKRSVRODF-UHFFFAOYSA-N vanillin acetate Chemical compound COC1=CC(C=O)=CC=C1OC(C)=O PZSJOBKRSVRODF-UHFFFAOYSA-N 0.000 description 13
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- PHCNQUJHXJQLQR-UHFFFAOYSA-N 4-hydroxy-3-methoxy-2-nitrobenzaldehyde Chemical compound COC1=C(O)C=CC(C=O)=C1[N+]([O-])=O PHCNQUJHXJQLQR-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000002101 lytic effect Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- CBRLWSXYXSFYSP-UHFFFAOYSA-N 2-aminopyrimidine-5-carboxylic acid Chemical compound NC1=NC=C(C(O)=O)C=N1 CBRLWSXYXSFYSP-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- ZYVGMXTZLDVOIW-UHFFFAOYSA-N 7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine Chemical compound C1=CC=2C3=NCCN3C(N)=NC=2C(OC)=C1OCCCN1CCOCC1 ZYVGMXTZLDVOIW-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- MFAGOHPTZMSDPF-UHFFFAOYSA-N N1C(=NCC1)C1=C(C(=C(OCCCN2CCOCC2)C=C1)OC)[N+](=O)[O-] Chemical compound N1C(=NCC1)C1=C(C(=C(OCCCN2CCOCC2)C=C1)OC)[N+](=O)[O-] MFAGOHPTZMSDPF-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 238000006396 nitration reaction Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000003880 polar aprotic solvent Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- ZROYKUBDBPTBSM-UHFFFAOYSA-N 6-(4,5-dihydro-1h-imidazol-2-yl)-2-methoxy-3-(3-morpholin-4-ylpropoxy)aniline Chemical compound COC1=C(N)C(C=2NCCN=2)=CC=C1OCCCN1CCOCC1 ZROYKUBDBPTBSM-UHFFFAOYSA-N 0.000 description 4
- QIZQMGSQCZIPGM-UHFFFAOYSA-N COC=1C(=C(C=O)C=CC=1OCCCN1CCOCC1)[N+](=O)[O-] Chemical compound COC=1C(=C(C=O)C=CC=1OCCCN1CCOCC1)[N+](=O)[O-] QIZQMGSQCZIPGM-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- XSYKRKGTOHLJJI-UHFFFAOYSA-N pyrimidine-5-carboxamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)C1=CN=CN=C1 XSYKRKGTOHLJJI-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- SMCVPMKCDDNUCQ-UHFFFAOYSA-N methyl 3,3-dimethoxypropanoate Chemical compound COC(OC)CC(=O)OC SMCVPMKCDDNUCQ-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- INFACQKUQJGVFF-UHFFFAOYSA-N 4-hydroxy-5-methoxy-2-nitrobenzaldehyde Chemical compound COC1=CC(C=O)=C([N+]([O-])=O)C=C1O INFACQKUQJGVFF-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- PQECODMSWJOUAT-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine;hydrochloride Chemical compound [Cl-].ClCCC[NH+]1CCOCC1 PQECODMSWJOUAT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XFQDGEQJZKIDKM-UHFFFAOYSA-N CC(CC=C1OCCCN2CCOCC2)(C2=NCCN2C(NC(c2cnc(N)nc2)=O)=N2)C2=C1OC Chemical compound CC(CC=C1OCCCN2CCOCC2)(C2=NCCN2C(NC(c2cnc(N)nc2)=O)=N2)C2=C1OC XFQDGEQJZKIDKM-UHFFFAOYSA-N 0.000 description 1
- HGHXNENFNAGCEY-UHFFFAOYSA-N CC1NC(N)=NC=C1/C(/O)=N/C1=Nc(c(OC)c(cc2)OCCCN3CCOCC3)c2C2=NCCN12 Chemical compound CC1NC(N)=NC=C1/C(/O)=N/C1=Nc(c(OC)c(cc2)OCCCN3CCOCC3)c2C2=NCCN12 HGHXNENFNAGCEY-UHFFFAOYSA-N 0.000 description 1
- 0 CN(C*1)C2N1C(NC(c1cnc(N)nc1)=O)=Nc1c2ccc(OCCCN2CCOCC2)c1OC Chemical compound CN(C*1)C2N1C(NC(c1cnc(N)nc1)=O)=Nc1c2ccc(OCCCN2CCOCC2)c1OC 0.000 description 1
- BJEFZCYLKNBYIN-UHFFFAOYSA-N COC(C(OCCCN1CCOCC1)=CCC1C2=NCCN2)=C1[N+]([O-])=O Chemical compound COC(C(OCCCN1CCOCC1)=CCC1C2=NCCN2)=C1[N+]([O-])=O BJEFZCYLKNBYIN-UHFFFAOYSA-N 0.000 description 1
- USMKZWAJXVJYBA-FARCUNLSSA-N COc(c(N1)c(cc2)C3=NCCN3/C1=N/C(c1cnc(N)nc1)=O)c2OCC/C=C/N1CCOCC1 Chemical compound COc(c(N1)c(cc2)C3=NCCN3/C1=N/C(c1cnc(N)nc1)=O)c2OCC/C=C/N1CCOCC1 USMKZWAJXVJYBA-FARCUNLSSA-N 0.000 description 1
- PIAZYBLGBSMNLX-UHFFFAOYSA-N ClCCCN1CCOCC1 Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 1
- 102000004353 Class I Phosphatidylinositol 3-Kinases Human genes 0.000 description 1
- 108010017000 Class I Phosphatidylinositol 3-Kinases Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- VXBOGDVAHHFQDB-UHFFFAOYSA-N N1C(=NCC1)C1=C(C(=C(OCCCN2CCOCC2)C=C1)OC)[N+](=O)[O-].CO Chemical compound N1C(=NCC1)C1=C(C(=C(OCCCN2CCOCC2)C=C1)OC)[N+](=O)[O-].CO VXBOGDVAHHFQDB-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101150058817 RRT1 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 108010037444 diisopropylglutathione ester Proteins 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HXJYQEAKVUQQLM-UHFFFAOYSA-N methyl 2-(dimethoxymethyl)-3-hydroxyprop-2-enoate Chemical compound COC(OC)C(=CO)C(=O)OC HXJYQEAKVUQQLM-UHFFFAOYSA-N 0.000 description 1
- MSXIOWULDXZJLX-UHFFFAOYSA-N n,n-dimethylpyrimidin-4-amine Chemical compound CN(C)C1=CC=NC=N1 MSXIOWULDXZJLX-UHFFFAOYSA-N 0.000 description 1
- FZIONDGWZAKCEX-UHFFFAOYSA-N nitrogen triiodide Chemical compound IN(I)I FZIONDGWZAKCEX-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- LVSJDHGRKAEGLX-UHFFFAOYSA-N oxolane;2,2,2-trifluoroacetic acid Chemical compound C1CCOC1.OC(=O)C(F)(F)F LVSJDHGRKAEGLX-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- NRTLTGGGUQIRRT-UHFFFAOYSA-N triethylazanium;bromide Chemical compound [Br-].CC[NH+](CC)CC NRTLTGGGUQIRRT-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
a)アルデヒドのニトリルへの変換のためのアンモニア/ヨウ素の使用(安全性の懸念)、および
b)イミダゾリン合成時の硫黄の使用(規模拡大の問題)
を回避することから、二つの問題を解決するものである。
前記式(5)の化合物は:
a)例えばナトリウムメトキシドなどの塩基と、任意に例えば1,4−ジオキサンなどの溶媒中、例えば還流下などのように加熱しながら反応させて、次に、
b)例えば室温まで冷却後、ギ酸メチルを加え、次に、
c)グアニジン塩酸塩を加え、次に、例えば還流下のように加熱し、次に、
d)水および例えば水酸化ナトリウムなどの塩基の水溶液を加え、次に加熱し、次に、
e)例えば塩酸などの鉱酸の水溶液を加え、
f)例えばジシクロヘキシルアミンなどのアミンを加え、濾過し、次に、
g)水酸化ナトリウムなどの強塩基の水溶液を加え、次に、
h)例えば塩酸などの鉱酸の水溶液を加えることで、
式(6b)の化合物:
a)任意に例えばジクロロメタンなどの溶媒中の溶液で、硝酸および硫酸と反応させ、次に
b)例えば炭酸カリウムなどの塩基を、任意に例えばメタノールなどの溶媒中で加えることで、
式(2)の化合物を提供する段階によって製造する。
使用される略称:
実施例で使用される下記の略称は、次の意味を有する。
Ac:アセチル
Boc:tert−ブチルオキシカルボニル
bm:広い多重線
br:広い
bs:広い一重線
c−:シクロ−
d:二重線
dd:二重線の二重線
DCM:ジクロロメタン
DME:1,2−ジメトキシエタン
DIPE:ジイソプロピルエーテル
DIPEA:N,N−ジイソプロピルエチルアミン
DMF:N,N−ジメチルホルムアミド
DMSO:ジメチルスルホキシド
EDCI:N−[3−(ジメチルアミノ)プロピル]−N′−エチルカルボジイミド塩酸塩
Eq:当量
ESI:エレクトロスプレーイオン化
HATU:N−[(ジメチルアミノ)(3H−[1,2,3]トリアゾロ[4,5−b]ピリジン−3−イルオキシ)メチレン]−N−メチルメタンアミニウム・ヘキサフルオロホスフェート
ヒューニッヒ塩基:N,N−ジイソプロピルエチルアミン
m:多重線
m.p.:融点(単位℃)
MS:質量分析
MW:分子量
NaOtBu:ナトリウムtert−ブトキシド;ナトリウム2−メチルプロパン−2−オレート
NMP:N−メチルピロリジノン
NMR:核磁気共鳴スペクトル測定:化学シフト(δ)はppm単位である。
qui:五重線
Rac:ラセミ
Rt:室温
r.t.:室温
RT:保持時間(単位:分)
s:一重線
t:三重線
TBAF:フッ化テトラブチルアンモニウム
TBTU:N−[(1H−ベンゾトリアゾール−1−イルオキシ)(ジメチルアミノ)メチレン]−N−メチルメタンアミニウム・テトラフルオロボレート
TEA:トリエチルアミン
TFA:トリフルオロ酢酸
THF:テトラヒドロフラン
TMS:トリメチルシリル
Ts:パラトルエンスルホニル;(トシル)
UPLC:超高速液体クロマトグラフィー。
実施例1:段階A1:4−ヒドロキシ−3−メトキシ−2−ニトロベンズアルデヒド(2−ニトロ−バニリン)(2)の製造
2−ニトロバニリン(2)を、マイクロリアクター中、酢酸バニリン(1)の流動ニトロ化によって合成した。硝酸(65重量%)3.94kgを、0℃で濃硫酸5.87kgに加えた(硝化酸)。酢酸バニリン1.5kgを、ジクロロメタン2.9kg(酢酸バニリン溶液)に溶かした。両方の溶液を、5℃でマイクロリアクター中、約8.0mL/分(硝化酸)および約4.0mL/分(酢酸バニリン溶液)の流量で反応させた。反応混合物を、3℃の水8kgに投入した。3時間後、流量を上昇させて10mL/分(硝化酸)および5.0mL/分(酢酸バニリン溶液)とした。さらに9時間後、流動反応を完了させた。層を室温で分離し、水相をジクロロメタン2リットルで抽出した。合わせた有機相を飽和重炭酸ナトリウム2リットルで洗浄し、次に水0.8リットルで洗浄した。ジクロロメタン溶液を減圧下に濃縮して約3リットルとし、メタノール3.9リットルを加え、ほぼ等体積を再度蒸留によって除去した。追加のメタノール3.9リットルを加え、溶液を濃縮して体積約3.5リットルとした。メタノール1.25kgを加え、次に炭酸カリウム2.26kgを加えた。混合物を30℃で3時間撹拌した。ジクロロメタン7.3kgおよび塩酸水溶液(10重量%)12.8kgを<30℃で加えた(pH0.5から1)。混合物を15分間撹拌し、層を分離した。有機層を濾過し、フィルターケーキをジクロロメタン0.5リットルで洗浄した。水層をジクロロメタン4.1kgで2回抽出した。合わせた有機層を減圧下に濃縮して約4リットルとした。トルエン3.41kgを加え、混合物を濃縮して、最終体積約4リットルとした。混合物を冷却して0℃とした。90分後、懸濁液を濾過した。回収固体を冷トルエンで洗浄し、乾燥させて、0.95kg(62%)を得た。
δ=3.95(s、3H)、7.37(s、1H)、7.51(s、1H)、10.16(s、1H)、11.11(brs、1H)。
4−(3−クロロプロピル)モルホリン塩酸塩854gをアセトニトリル19.4リットルに懸濁させ、混合物を室温で50分間撹拌した。混合物を濾過し、残留物をアセトニトリル0.7リットルで洗浄した。濾液を、2−ニトロバニリン700gおよび炭酸カリウム1.96kgのアセトニトリル(7リットル)中懸濁液に室温で約2時間の期間をかけて投入した。反応混合物を加熱還流し、3時間還流撹拌した。混合物を冷却して室温とし、濾過した。残留物をアセトニトリルで2回洗浄した。濾液を減圧下に濃縮し、残留物を酢酸エチル5.6リットルに溶かした。この溶液を10重量%塩化ナトリウム水溶液7リットル、次に1%塩化ナトリウム水溶液7.7リットルで洗浄した。溶媒除去後、粘稠残留物約1.14kgを、次の段階の溶媒であるジクロロメタン2.3リットルに溶かした。
前の反応からのジクロロメタン溶液6.1kg(3−メトキシ−4−[3−(モルホリン−4−イル)プロポキシ]−2−ニトロベンズアルデヒド(実施例2)5.25モルを含有)をジクロロメタン25.7リットルで希釈した。10分間の期間をかけてエチレンジアミン836gを加え、反応混合物を室温で1時間撹拌した。冷却して0℃とした後、N−ブロモコハク酸イミド2.476kgを3回に分けて加えた。反応混合物を、30分以内で昇温させて25℃とし、再度冷却して0℃とした。反応混合物を0℃で105分間撹拌した。飽和重炭酸ナトリウム水溶液2.3リットルを加え、次に水酸化ナトリウム水溶液(20重量%)5.4リットルを加えて、溶液をpH14に調節した。水5.8リットルを加え、混合物を昇温させて室温とした。有機相を分離し、水12.9リットルで洗浄し、硫酸ナトリウム1kgで脱水した。濾液を溶媒留去した(残留物1.87kg)。
メタノール(5kg)(炭酸カリウムで飽和)中の4−{3−[4−(4,5−ジヒドロ−1H−イミダゾール−2−イル)−2−メトキシ−3−ニトロフェノキシ]プロピル}モルホリン(4)625gおよび触媒(5%Pd/1%Fe/炭素、含水品)63gの混合物を10MPa(100バール)水素圧下に40℃で24時間撹拌した。触媒を不活性ガス雰囲気下に濾去し、メタノールで洗浄して、生成物溶液6.1kgを得た。後処理のため、いくつかのバッチの生成物溶液を合わせた。真空蒸留によって溶媒をトルエンに切り替えた。トルエン生成物溶液を75℃で濾過し、生成物が沈殿するまで減圧下に濃縮した。混合物を濾過し、固体を冷トルエンで洗浄し、乾燥させた。4−{3−[4−(4,5−ジヒドロ−1H−イミダゾール−2−イル)−2−メトキシ−3−ニトロフェノキシ]プロピル}モルホリン(4)5kgの水素化によって、3.3kg(71%)を得た。
トリエチルアミン375mLを、ジクロロメタン3リットル中の6−(4,5−ジヒドロ−1H−イミダゾール−2−イル)−2−メトキシ−3−[3−(モルホリン−4−イル)プロポキシ]アニリン(5)300gに加えた。溶液を冷却して0℃とし、ブロモシアニド98gのジクロロメタン(300mL)中溶液を約0.5時間以内に加えた。得られた懸濁液を−5から0℃で1時間、次に10℃で2時間撹拌した。反応混合物を飽和重炭酸ナトリウム水溶液675mLで3回洗浄した。有機相を減圧下に濃縮した。イソプロパノール1.1リットルを加え、混合物を加熱して約75℃とした。得られた溶液を終夜で冷却して室温とし、次に5℃まで冷却し、2時間撹拌した。生成物を濾去し、冷イソプロパノールで2回洗浄し、乾燥させて、230g(70%)を得た。
メチル3,3−ジメトキシプロパノエート1kgを1,4−ジオキサン7リットルに溶かした。ナトリウムメトキシド溶液1.58kg(30重量%メタノール中溶液)を加えた。混合物を加熱還流し、蒸留物約4.9kgを除去した。得られた懸濁液を冷却して室温とし、ギ酸メチル0.5kgを加えた。反応混合物を終夜撹拌し、次にグアニジン塩酸塩0.71kgを加え、反応混合物を室温で2時間撹拌した。反応混合物を加熱還流し、2時間撹拌した。水13.5リットルを加え、次に水酸化ナトリウム水溶液(45重量%)0.72kgを加えた。反応混合物をさらに0.5時間加熱還流し、次に冷却して50℃とした。塩酸水溶液(25重量%)0.92kgを、pH6に達するまで加えた。シード接種結晶を加え、追加の塩酸水溶液(25重量%)0.84kgを、pH2に達するまで50℃で加えた。混合物を冷却して20℃とし、終夜撹拌した。懸濁液を濾過し、回収固体を水で洗浄し、次にメタノールで洗浄して、0.61kg(65%)を得た。
7−メトキシ−8−[3−(モルホリン−4−イル)プロポキシ]−2,3−ジヒドロイミダゾ[1,2−c]キナゾリン−5−アミン600g、2−アミノピリミジン−5−カルボン酸306g、N,N−ジメチル−4−アミノピリジン204g、N−[3−(ジメチルアミノ)プロピル]−N′−エチルカルボジイミド塩酸塩480gおよびN,N−ジメチルホルムアミド1500gの混合物を室温で15時間撹拌した。混合物を濾過し、フィルターケーキをN,N−ジメチルホルムアミドと次にエタノールで洗浄した。回収固体を真空乾燥して、コパンリシブ769g(96%)を得た。
コパンリシブ366gの水(1015g)中懸濁液に、pH3から4に達するまで20℃(±2℃)に温度を維持しながら、塩酸水溶液(32%)183gを加えた。得られた混合物を室温でさらに10分間撹拌し、濾過し、フィルターケーキを追加の水82gで洗浄した。塩酸水溶液(32%)を用いて、濾液をpH1.8から2.0に調節した。混合物を室温で10分間撹拌し、エタノール(100%)146gを加え、さらに10分間撹拌した。シード結晶1gを加え、次に5時間以内でエタノール1592gを加えた。得られた物質を濾過によって除去し、水−エタノール混合物で洗浄し、真空乾燥して、コパンリシブ2塩酸塩410g(97%)を得た。
Claims (9)
- コパンリシブ(7):
次の段階:
段階A6、すなわち
下記式(6)の化合物:
前記式(6)の化合物は:
下記式(5)の化合物:
前記式(5)の化合物は:
式(4)の化合物:
- 前記式(6b)の化合物:
式(6a)の化合物:
a)例えばナトリウムメトキシドなどの塩基と、任意に例えば1,4−ジオキサンなどの溶媒中、例えば還流下などのように加熱しながら反応させて、次に、
b)例えば室温まで冷却後、ギ酸メチルを加え、次に、
c)グアニジン塩酸塩を加え、次に、例えば還流下のように加熱し、次に、
d)水および例えば水酸化ナトリウムなどの塩基の水溶液を加え、次に加熱し、次に、
e)例えば塩酸などの鉱酸の水溶液を加え、
f)例えばジシクロヘキシルアミンなどのアミンを加え、濾過し、次に、
g)水酸化ナトリウムなどの強塩基の水溶液を加え、次に、
h)例えば塩酸などの鉱酸の水溶液を加えることで、任意に次の段階の前に精製される、式(6b)の化合物:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14192202.1 | 2014-11-07 | ||
EP14192202.1A EP3018131A1 (en) | 2014-11-07 | 2014-11-07 | Synthesis of copanlisib and its dihydrochloride salt |
PCT/EP2015/075765 WO2016071426A1 (en) | 2014-11-07 | 2015-11-05 | Synthesis of copanlisib and its dihydrochloride salt |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017536352A true JP2017536352A (ja) | 2017-12-07 |
JP6691114B2 JP6691114B2 (ja) | 2020-04-28 |
Family
ID=51866060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017523873A Active JP6691114B2 (ja) | 2014-11-07 | 2015-11-05 | コパンリシブおよびそれの2塩酸塩の合成 |
Country Status (34)
Country | Link |
---|---|
US (1) | US10035803B2 (ja) |
EP (2) | EP3018131A1 (ja) |
JP (1) | JP6691114B2 (ja) |
KR (1) | KR102562286B1 (ja) |
CN (1) | CN107074776B (ja) |
AR (1) | AR102568A1 (ja) |
AU (1) | AU2015341779B2 (ja) |
BR (1) | BR112017009471B1 (ja) |
CA (1) | CA2966796C (ja) |
CL (1) | CL2017001130A1 (ja) |
CO (1) | CO2017004533A2 (ja) |
DK (1) | DK3215507T3 (ja) |
EA (1) | EA031248B1 (ja) |
ES (1) | ES2716730T3 (ja) |
HR (1) | HRP20190527T8 (ja) |
HU (1) | HUE042794T2 (ja) |
IL (1) | IL251586B (ja) |
JO (1) | JO3487B1 (ja) |
LT (1) | LT3215507T (ja) |
MX (1) | MX365111B (ja) |
MY (1) | MY183123A (ja) |
NZ (1) | NZ730843A (ja) |
PE (1) | PE20170951A1 (ja) |
PL (1) | PL3215507T3 (ja) |
PT (1) | PT3215507T (ja) |
RS (1) | RS58494B1 (ja) |
SG (1) | SG11201702999XA (ja) |
SI (1) | SI3215507T1 (ja) |
TR (1) | TR201904346T4 (ja) |
TW (1) | TWI697494B (ja) |
UA (1) | UA118999C2 (ja) |
UY (1) | UY36396A (ja) |
WO (1) | WO2016071426A1 (ja) |
ZA (1) | ZA201703866B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
JP6368353B2 (ja) | 2013-04-08 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | 置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン類のリンパ腫治療への使用 |
EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
US10406162B2 (en) | 2015-03-09 | 2019-09-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
CA3016584A1 (en) | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083659A1 (fr) * | 2001-04-13 | 2002-10-24 | Kaneka Corporation | Diamine, dianhydride acide, composition polyimide renfermant un groupe reactif et obtenue au moyen de ces elements, et procedes de production associes |
JP2004521875A (ja) * | 2000-12-01 | 2004-07-22 | エレジーレ ソシエタ ペル アチオニ | 1−(アミノメチル)シクロヘキサン酢酸の調製方法 |
JP2005502661A (ja) * | 2001-08-15 | 2005-01-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 無脊椎有害生物を防除するためのo−複素環式置換アリールアミド |
JP2010511718A (ja) * | 2006-12-05 | 2010-04-15 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 高増殖性疾患及び血管形成関連疾患の治療に有用な置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体 |
JP2011518114A (ja) * | 2008-01-14 | 2011-06-23 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類 |
JP2014510119A (ja) * | 2011-04-05 | 2014-04-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA82205C2 (en) * | 2002-09-30 | 2008-03-25 | Байер Фармасьютикалз Корпорейшн | Fused azole-pyrimidine derivatives |
PE20121471A1 (es) | 2009-11-04 | 2012-11-01 | Novartis Ag | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek |
-
2014
- 2014-11-07 EP EP14192202.1A patent/EP3018131A1/en not_active Withdrawn
-
2015
- 2015-05-11 UA UAA201705431A patent/UA118999C2/uk unknown
- 2015-11-03 JO JOP/2015/0273A patent/JO3487B1/ar active
- 2015-11-05 CA CA2966796A patent/CA2966796C/en active Active
- 2015-11-05 NZ NZ730843A patent/NZ730843A/en unknown
- 2015-11-05 AU AU2015341779A patent/AU2015341779B2/en active Active
- 2015-11-05 KR KR1020177011704A patent/KR102562286B1/ko active IP Right Grant
- 2015-11-05 ES ES15790141T patent/ES2716730T3/es active Active
- 2015-11-05 PE PE2017000848A patent/PE20170951A1/es unknown
- 2015-11-05 BR BR112017009471-1A patent/BR112017009471B1/pt active IP Right Grant
- 2015-11-05 SI SI201530660T patent/SI3215507T1/sl unknown
- 2015-11-05 RS RS20190398A patent/RS58494B1/sr unknown
- 2015-11-05 HU HUE15790141A patent/HUE042794T2/hu unknown
- 2015-11-05 MX MX2017005891A patent/MX365111B/es active IP Right Grant
- 2015-11-05 PT PT15790141T patent/PT3215507T/pt unknown
- 2015-11-05 US US15/524,478 patent/US10035803B2/en active Active
- 2015-11-05 DK DK15790141.4T patent/DK3215507T3/en active
- 2015-11-05 SG SG11201702999XA patent/SG11201702999XA/en unknown
- 2015-11-05 EA EA201790982A patent/EA031248B1/ru not_active IP Right Cessation
- 2015-11-05 PL PL15790141T patent/PL3215507T3/pl unknown
- 2015-11-05 LT LTEP15790141.4T patent/LT3215507T/lt unknown
- 2015-11-05 MY MYPI2017701571A patent/MY183123A/en unknown
- 2015-11-05 TR TR2019/04346T patent/TR201904346T4/tr unknown
- 2015-11-05 WO PCT/EP2015/075765 patent/WO2016071426A1/en active Application Filing
- 2015-11-05 JP JP2017523873A patent/JP6691114B2/ja active Active
- 2015-11-05 CN CN201580059995.1A patent/CN107074776B/zh active Active
- 2015-11-05 EP EP15790141.4A patent/EP3215507B1/en active Active
- 2015-11-06 TW TW104136727A patent/TWI697494B/zh active
- 2015-11-06 UY UY0001036396A patent/UY36396A/es not_active Application Discontinuation
- 2015-11-06 AR ARP150103617A patent/AR102568A1/es unknown
-
2017
- 2017-04-05 IL IL251586A patent/IL251586B/en active IP Right Grant
- 2017-05-05 CO CONC2017/0004533A patent/CO2017004533A2/es unknown
- 2017-05-05 CL CL2017001130A patent/CL2017001130A1/es unknown
- 2017-06-06 ZA ZA2017/03866A patent/ZA201703866B/en unknown
-
2019
- 2019-03-18 HR HRP20190527TT patent/HRP20190527T8/hr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004521875A (ja) * | 2000-12-01 | 2004-07-22 | エレジーレ ソシエタ ペル アチオニ | 1−(アミノメチル)シクロヘキサン酢酸の調製方法 |
WO2002083659A1 (fr) * | 2001-04-13 | 2002-10-24 | Kaneka Corporation | Diamine, dianhydride acide, composition polyimide renfermant un groupe reactif et obtenue au moyen de ces elements, et procedes de production associes |
JP2005502661A (ja) * | 2001-08-15 | 2005-01-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 無脊椎有害生物を防除するためのo−複素環式置換アリールアミド |
JP2010511718A (ja) * | 2006-12-05 | 2010-04-15 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 高増殖性疾患及び血管形成関連疾患の治療に有用な置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体 |
JP2011518114A (ja) * | 2008-01-14 | 2011-06-23 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類 |
JP2014510119A (ja) * | 2011-04-05 | 2014-04-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類 |
Non-Patent Citations (1)
Title |
---|
HIROMICHI FUJIOKA; ET AL: "ONE-POT SYNTHESIS OF IMIDAZOLINES FROM ALDEHYDES: DETAILED STUDY ABOUT SOLVENTS AND SUBSTRATES", TETRAHEDRON, vol. VOL:63, NR:3, JPN5017009128, 13 December 2006 (2006-12-13), NL, pages 638 - 643, ISSN: 0004057821 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6691114B2 (ja) | コパンリシブおよびそれの2塩酸塩の合成 | |
JP6691115B2 (ja) | コパンリシブおよびそれの二塩酸塩の合成 | |
CA3056712A1 (en) | Synthesis of mcl-1 inhibitor | |
JP2017522306A (ja) | 3−(3−クロロ−1h−ピラゾール−1−イル)ピリジンの製造方法 | |
AU2017387801B2 (en) | Methods for the preparation of 6-aminoisoquinoline | |
WO2016071382A1 (en) | Synthesis of pi3k inhibitor and salts thereof | |
CN113444023B (zh) | 一种叔丁氧羰基保护的氨类化合物的合成方法及应用 | |
CN117677617A (zh) | 一种乙肝病毒核衣壳抑制剂的制备方法 | |
WO2016071380A1 (en) | Synthesis of pi3k inhibitor and salts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180919 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190618 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200317 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200409 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6691114 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |